Dada Reyad
Department of Oncology MBC J-64, King Faisal Specialist Hospital and Research Center, P.O. Box 40047, Jeddah, 21499, Kingdom of Saudi Arabia.
College of Medicine, Al-Faisal University, Riyadh, Kingdom of Saudi Arabia.
Ann Hematol. 2018 Apr;97(4):555-561. doi: 10.1007/s00277-017-3226-0. Epub 2018 Jan 10.
Cancer cells are able to induce immune system tolerance through different mechanisms. Recent achievements in the understanding of tumor microenvironment, invasion, and metastasizing have contributed to accelerated drug developments and approvals. Hodgkin lymphoma (HL) cells are the minority in a lymphocyte-rich microenvironment of HL tissue. The program death-1 (PD-1)/PD-ligand-1 checkpoint is one of the known effective pathways in classical HL to escape the immune system cells. The approval of PD-1 inhibitors in different cancer types with exciting response rates is truly revolutionizing our treatment armamentarium against cancer in general and classical HL in specific. Although the disease is one of the most curable tumors, we still need better outcome with more gentle treatment, especially for relapsed and refractory (r/r) patients. In this article, we review the current literature on immune checkpoint inhibitors and currently ongoing studies with nivolumab and pembrolizumab in r/r classical HL.
癌细胞能够通过不同机制诱导免疫系统耐受。在理解肿瘤微环境、侵袭和转移方面的最新成果推动了药物开发与审批的加速。霍奇金淋巴瘤（HL）细胞在富含淋巴细胞的HL组织微环境中占少数。程序性死亡-1（PD-1）/PD-配体-1检查点是经典HL中已知的逃避免疫系统细胞的有效途径之一。PD-1抑制剂在不同癌症类型中获批且反应率令人振奋，这确实正在彻底改变我们对抗癌症的总体治疗手段，尤其是针对经典HL的治疗手段。尽管该疾病是最可治愈的肿瘤之一，但我们仍需要通过更温和的治疗获得更好的疗效，特别是对于复发难治（r/r）患者。在本文中，我们综述了关于免疫检查点抑制剂的当前文献以及目前正在进行的纳武单抗和派姆单抗治疗r/r经典HL的研究。
